AssuredPartners Investment Advisors LLC Has $869,000 Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

AssuredPartners Investment Advisors LLC raised its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 133.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 69,111 shares of the company's stock after acquiring an additional 39,500 shares during the period. AssuredPartners Investment Advisors LLC owned about 0.07% of ARS Pharmaceuticals worth $869,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. acquired a new position in ARS Pharmaceuticals in the first quarter valued at about $189,000. Advisor Resource Council acquired a new position in shares of ARS Pharmaceuticals during the first quarter worth about $3,135,000. Janney Montgomery Scott LLC boosted its position in shares of ARS Pharmaceuticals by 1,552.1% during the first quarter. Janney Montgomery Scott LLC now owns 448,669 shares of the company's stock worth $5,644,000 after buying an additional 421,511 shares during the period. Rhumbline Advisers boosted its position in shares of ARS Pharmaceuticals by 7.1% during the first quarter. Rhumbline Advisers now owns 69,766 shares of the company's stock worth $878,000 after buying an additional 4,603 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of ARS Pharmaceuticals by 4,319.7% during the first quarter. GAMMA Investing LLC now owns 3,359 shares of the company's stock worth $420,000 after buying an additional 3,283 shares during the period. 68.16% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SPRY has been the subject of several recent research reports. Wall Street Zen raised ARS Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday. Scotiabank initiated coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 price objective for the company. Finally, William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $31.00.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, Director Laura Shawver sold 50,002 shares of the stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $12.30, for a total transaction of $615,024.60. Following the transaction, the director now owns 210,346 shares in the company, valued at approximately $2,587,255.80. This trade represents a 19.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Brent L. Saunders sold 120,000 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $14.25, for a total value of $1,710,000.00. The disclosure for this sale can be found here. Insiders have sold 337,971 shares of company stock worth $4,721,888 over the last 90 days. Company insiders own 33.50% of the company's stock.

ARS Pharmaceuticals Stock Up 0.7%

NASDAQ SPRY traded up $0.12 during trading hours on Friday, hitting $18.20. 3,883,996 shares of the company traded hands, compared to its average volume of 1,324,436. The business's 50-day moving average is $14.63 and its 200-day moving average is $13.03. ARS Pharmaceuticals, Inc. has a twelve month low of $8.35 and a twelve month high of $18.90. The company has a debt-to-equity ratio of 0.30, a quick ratio of 10.74 and a current ratio of 11.00. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -113.74 and a beta of 0.84.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, meeting the consensus estimate of ($0.35). ARS Pharmaceuticals had a negative return on equity of 6.94% and a negative net margin of 16.11%. The firm had revenue of $7.97 million during the quarter, compared to analysts' expectations of $7.48 million. Sell-side analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.